

Egetis Therapeutics - Continued progress in Q4

Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Egetis Therapeutics - Continued progress in Q4](#)